Press release
CRBSI Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Leonard-Meron Biosciences, Inc.
CRBSI Pipeline Insights, DelveInsight
Catheter-related bloodstream infection Overview:
Catheter-related bloodstream infection (CRBSI) is characterized by the presence of bacteremia originating from an intravenous catheter. It is among the most common, severe, and expensive complications of central venous catheterization and is the leading cause of hospital-acquired bacteremia. Intravascular catheters are essential in modern medical care, particularly for critically ill patients, as they facilitate the administration of fluids, medications, blood products, nutritional support, and hemodynamic monitoring.
Compared to other medical devices, central venous catheters (CVCs) carry the highest risk of device-related infections and significantly contribute to patient morbidity and mortality. They are the primary source of bacteremia and septicemia in hospitalized patients. The majority of CRBSI cases are linked to CVCs, with research indicating that the risk of developing CRBSI is up to 64 times higher with CVCs than with peripheral venous catheters.
Request for a detailed insights report on CRBSI pipeline insights @ https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"CRBSI Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the CRBSI Therapeutics Market.
Key Takeaways from the CRBSI Pipeline Report
DelveInsight's CRBSI pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for CRBSI treatment.
Key CRBSI companies such as Leonard-Meron Biosciences, Inc., and others are evaluating new drugs for CRBSI to improve the treatment landscape.
Promising CRBSI pipeline therapies in various stages of development include Mino-Lok, and others.
Recent breakthroughs in the CRBSI Pipeline Segment:
On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved DefenCath® to reduce the incidence of CRBSIs in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). This approval marks DefenCath® as the first and only FDA-approved antimicrobial catheter lock solution in the United States.
CRBSI Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the CRBSI Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRBSI treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CRBSI market.
Download our free sample page report on CRBSI pipeline insights @ https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
CRBSI Emerging Drugs
Mino-Lok: Leonard-Meron Biosciences, Inc.
CRBSI Companies
More than five key companies are actively developing therapies for Catheter-related Bloodstream Infection. Among them, Leonard-Meron Biosciences, Inc. and other companies have drug candidates in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight's report covers around 5+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
CRBSI pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
CRBSI Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging CRBSI Therapies and Key Companies: CRBSI Clinical Trials and advancements @ https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
CRBSI Pipeline Therapeutic Assessment
• CRBSI Assessment by Product Type
• CRBSI By Stage
• CRBSI Assessment by Route of Administration
• CRBSI Assessment by Molecule Type
Download CRBSI Sample report to know in detail about the CRBSI treatment market @ CRBSI Therapeutic Assessment @ https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. CRBSI Current Treatment Patterns
4. CRBSI - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. CRBSI Late-Stage Products (Phase-III)
7. CRBSI Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CRBSI Discontinued Products
13. CRBSI Product Profiles
14. CRBSI Key Companies
15. CRBSI Key Products
16. Dormant and Discontinued Products
17. CRBSI Unmet Needs
18. CRBSI Future Perspectives
19. CRBSI Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the CRBSI Pipeline Reports Offerings: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CRBSI Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Leonard-Meron Biosciences, Inc. here
News-ID: 3907816 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for CRBSI
CRBSI Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment A …
DelveInsight's, "Catheter-related Bloodstream Infection -Pipeline Insight, 2025," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Catheter-related Bloodstream Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over five key companies are actively…
Global CRBSI Treatment Market to Experience Significant Growth to reach USD 2,90 …
The global CRBSI treatment market is on a significant growth trajectory, projected to experience a compound annual growth rate (CAGR) of 5.4% between 2025 and 2035. This growth is being propelled by multiple factors, including the rising burden of hospital-acquired infections (HAIs), increased use of central venous catheters (CVC), and continual advancements in antimicrobial therapies. These key drivers, along with ongoing innovations in infection prevention and management, are expected to…
CRBSI Treatment Market Expansion on Track to Hit US$ 2.2 Bn by 2030, Says Persis …
The catheter-related bloodstream infection (CRBSI) treatment market is witnessing steady growth, driven by the rising prevalence of healthcare-associated infections (HAIs), the increasing use of intravascular catheters, and growing awareness about infection prevention protocols. With hospitals and healthcare providers under pressure to reduce infection rates and improve patient outcomes, the market for CRBSI treatments-including antibiotics, catheters, and preventive solutions-is evolving rapidly.
✅ Get a Sample Copy of Research Report (Use Corporate…
CRBSI Treatment Market Expected to Reach USD 2.2 Billion by 2030 | Persistence M …
The global catheter-related bloodstream infection (CRBSI) treatment market is poised for significant expansion, projected to rise from US$1.5 billion in 2023 to US$2.2 billion by 2030, reflecting a CAGR of 5.7%. The market's growth is driven by the rising prevalence of chronic diseases necessitating long-term catheter use, increased healthcare expenditures, and advancements in catheter technologies.
Among the various segments, antibiotic-based treatments hold the largest share, while the echinocandin antifungal segment is…
Catheter-Related Bloodstream Infection (CRBSI) Drugs Market Size, Share, Growth, …
Global Catheter-Related Bloodstream Infection (CRBSI) Drugs Market to Witness Substantial Growth by 2031
The global market for Catheter-Related Bloodstream Infection (CRBSI) drugs has shown remarkable growth in recent years, reaching US$ million in 2022. According to the latest industry analysis, this market is projected to surge to US$ million by 2031, with a robust Compound Annual Growth Rate (CAGR) of during the forecast period spanning 2024 to 2031.
CRBSI is…
Catheter-related bloodstream infection (CRBSI) Market Insight, Epidemiology and …
Catheter-related bloodstream infection (CRBSI) Market research report is the new statistical data source added by Infinity Business Insights.
CRBSIs (central venous catheter-related bloodstream infections) are a leading source of hospital-acquired illness, with high rates of morbidity, death, and expense. The severity of the consequences is determined by the organisms involved, the underlying pre-morbid states, the timeliness, and the suitability of the treatment/interventions received.
Note – In order to provide more accurate…
